SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Al Halabi S)
 

Sökning: WFRF:(Al Halabi S) > Hsp90 inhibition by...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003632naa a2200529 4500
001oai:gup.ub.gu.se/223592
003SwePub
008240528s2015 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/2235922 URI
0247 a https://doi.org/10.1016/j.canlet.2015.07.0252 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Steinmann, S.4 aut
2451 0a Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma
264 1b Elsevier BV,c 2015
520 a Liposarcoma is one of the most common soft tissue sarcomas in adults. Recognized histological subtypes include well differentiated/dedifferentiated liposarcoma (WD/DDLS), myxoid liposarcoma (MLS) and pleomorphic liposarcoma. Currently, there are no proper subtype-specific treatments due to the genetic, histological and clinical heterogeneity of the liposarcoma subentities. In the past decade, the rising understanding of the various genetic and molecular aberrations in liposarcoma led to the development of novel alternative therapeutic strategies. One such therapy is the inhibition of the heat shock protein 90 (Hsp90) which is overexpressed in liposarcomas. In this study, we dissect the functional role of a novel potent Hsp90 inhibitor NVP-AUY922 (AUY922) in different cell lines of myxoid (ML5402, MLS1765) and undifferentiated (SW872) liposarcomas. We show that compared with 17-AAG treatment, lower concentrations of AUY922 achieve markedly cytotoxic effects on tumor cell viability. Combination treatment of AUY922 (20 nM) with Doxorubicin (300 nM) yielded a further reduction in cell viability in comparison to Doxorubicin alone. In vivo, we document an inhibition of tumor growth after AUY922 treatment. Further analyses revealed that Hsp90-inhibition induces apoptotic cell death and cell cycle arrest. In addition, we report striking perturbations of subtype-specific pattern in Raf/MEK/ERK and PI3K signaling after AUY922 application. In conclusion, our results provide evidence that Hsp90-inhibition by AUY922 may be a promising alternative therapeutic strategy for myxoid liposarcoma patients. (C) 2015 Published by Elsevier Ireland Ltd.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Liposarcoma
653 a Hsp90-inhibition
653 a NVP-AUY922
653 a Myxoid
653 a GASTROINTESTINAL STROMAL TUMOR
653 a CANCER CELLS
653 a PATHWAY
653 a APOPTOSIS
653 a KINASE
653 a GROWTH
653 a EXTREMITY
653 a SURVIVAL
653 a IMATINIB
653 a Oncology
7001 a Gali-Muhtasib, H.4 aut
7001 a Huebner, K.4 aut
7001 a Al-Halabi, R.4 aut
7001 a Abou Merhi, R.4 aut
7001 a Åman, Pierre,d 1953u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,Institutionen för biomedicin, avdelningen för patologi,Institute of Biomedicine, Department of Pathology4 aut0 (Swepub:gu)xamapi
7001 a Agaimy, A.4 aut
7001 a Haller, F.4 aut
7001 a Schneider-Stock, R.4 aut
7102 a Göteborgs universitetb Sahlgrenska Cancer Center4 org
7730 t Cancer Lettersd : Elsevier BVg 367:2, s. 147-156q 367:2<147-156x 0304-3835
8564 8u https://gup.ub.gu.se/publication/223592
8564 8u https://doi.org/10.1016/j.canlet.2015.07.025

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy